The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 1,001–1,025 of 1,025
Wu, J., Zhou, S.-L., Pi, L.-H., Shi, X.-J., Ma, L.-R., Chen, Z., Qu, M.-L., Li, X., Nie, S.-D., Liao, D.-F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17257 · Cited by 50
Perez, S. E., Sherwood, C. C., Cranfield, M. R., Erwin, J. M., Mudakikwa, A., Hof, P. R., & Mufson, E. J. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.12.017 · Cited by 50
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
“End-Stage” Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?
Abner, E. L., Kryscio, R. J., Schmitt, F. A., SantaCruz, K. S., Jicha, G. A., Lin, Y., Neltner, J. M., Smith, C. D., Van Eldik, L. J., & Nelson, P. T. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101980 · Cited by 49
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
NPT088 reduces both amyloid‐β and tau pathologies in transgenic mice
Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47
Antecedent Biomarkers of Alzheimer’s Disease: The Adult Children Study
Coats, M., & Morris, J. C. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281881 · Cited by 44
Further understanding of tau phosphorylation: implications for therapy
Medina, M., & Avila, J. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1000864 · Cited by 41
Nakaya, M., Sato, N., Matsuda, H., Maikusa, N., Shigemoto, Y., Sone, D., Yamao, T., Ogawa, M., Kimura, Y., Chiba, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12356 · Cited by 41
Dickson, T. C., Saunders, H. L., & Vickers, J. C. (1997) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1997.tb01325.x · Cited by 40
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Are Aβ and Its Derivatives Causative Agents or Innocent Bystanders in AD?
Robakis, N. K. (2010) · Neurodegenerative Diseases · doi:10.1159/000266476 · Cited by 32
Preserved autophagy in cognitively intact non‐demented individuals with Alzheimer's neuropathology
Tumurbaatar, B., Fracassi, A., Scaduto, P., Guptarak, J., Woltjer, R., Jupiter, D., & Taglialatela, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13074 · Cited by 32
Zimmer, E. R., Leuzy, A., Bhat, V., Gauthier, S., & Rosa-Neto, P. (2014) · Translational Neurodegeneration · doi:10.1186/2047-9158-3-6 · Cited by 30
Chen, Y.-C., Ton That, V., Ugonna, C., Liu, Y., Nadel, L., & Chou, Y.-H. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113778119 · Cited by 29
Del Tredici, K., & Braak, H. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.016 · Cited by 27
Senescence in aging and disorders of the central nervous system
Swenson, B. L., Meyer, C. F., Bussian, T. J., & Baker, D. J. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.01.002 · Cited by 24
Chen, X., Sun, G., Feng, L., Tian, E., & Shi, Y. (2025) · Communications Biology · doi:10.1038/s42003-024-07401-0 · Cited by 23
Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons
Oakley, D. H., Klickstein, N., Commins, C., Chung, M., Dujardin, S., Bennett, R. E., Hyman, B. T., & Frosch, M. P. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.2590-20.2021 · Cited by 18
Self-citationCurrent insights into apolipoprotein E and the immune response in Alzheimer's disease
Lin, P. B., & Holtzman, D. M. (2024) · Immunological Reviews · doi:10.1111/imr.13414 · Cited by 19
Younes, K., Smith, V., Johns, E., Carlson, M. L., Winer, J., He, Z., Henderson, V. W., Greicius, M. D., Young, C. B., & Mormino, E. C. (2024) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2024.05.002 · Cited by 13
Bai, Q., & Zhao, Z. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2147 · Cited by 12
Kim, E.-J., Vatsavayai, S., & Seeley, W. W. (2016) · The Behavioral Neurology of Dementia · doi:10.1017/9781139924771.008 · Cited by 7
Network analysis identifies strain-dependent response to tau and tau seeding-associated genes
Acri, D. J., You, Y., Tate, M. D., Karahan, H., Martinez, P., McCord, B., Sharify, A. D., John, S., Kim, B., Dabin, L. C., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20230180 · Cited by 3
“Importantly, hyperphosphorylated tau has been shown to cause neuronal cell death (Lee et al., 2011) and to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
